128 related articles for article (PubMed ID: 36971307)
21. Clinical characteristics, initial treatment, and prognosis of mycosis fungoides and Sézary syndrome: A retrospective, single-center study at the Centre Hospitalier Universitaire of Quebec.
Lachance M; Thibeault MM
Ann Dermatol Venereol; 2023 Dec; 150(4):276-280. PubMed ID: 37777355
[No Abstract] [Full Text] [Related]
22. Pathophysiology of cutaneous T-cell lymphomas: Perspective from a French referral centre.
De Masson A; Lazaridou I; Moins-Teisserenc H; Ram-Wolff C; Giustiniani J; Bagot M; Battistella M; Bensussan A
Immunol Lett; 2024 May; 268():106871. PubMed ID: 38801999
[TBL] [Abstract][Full Text] [Related]
23. [Epidemiologie reifzelliger T- und NK-Zell-Lymphome in Deutschland - Eine repräsentative Querschnittanalyse von GKV-Routinedaten: Epidemiology of mature T/NK-cell lymphomas in Germany - A representative cross-sectional study based on SHI claims data].
Assaf C; Dobos G; Zech IM; Doess A; May M; Jadasz J
J Dtsch Dermatol Ges; 2023 Nov; 21(11):1320-1328. PubMed ID: 37946651
[TBL] [Abstract][Full Text] [Related]
24. Alopecia areata-like presentations with mogamulizumab therapy.
Kincaid CM; Sharma AN; Lee BA; Pinter-Brown LC; Smith J; Linden K; Mesinkovska NA
JAAD Case Rep; 2023 Nov; 41():71-74. PubMed ID: 37877094
[No Abstract] [Full Text] [Related]
25. Mogamulizumab combined with extracorporeal photopheresis for the treatment of refractory mycosis fungoides and Sézary syndrome. Report of seven cases.
Rubio-Muniz CA; Sánchez-Velázquez A; Arroyo-Andrés J; Agud-de Dios M; Tarín-Vicente EJ; Falkenhain-López D; Ortiz-Romero PL
J Eur Acad Dermatol Venereol; 2024 Jan; 38(1):e102-e105. PubMed ID: 37611255
[No Abstract] [Full Text] [Related]
26. The Interferon story continues: EORTC CLTG Study Explores Pegylated Interferon Alpha-2α's Role in Treating Mycosis Fungoides/Sézary Syndrome.
Stadler R
Br J Dermatol; 2024 May; ():. PubMed ID: 38703059
[No Abstract] [Full Text] [Related]
27. SEZARY SYNDROME: Report of Two Cases.
Rai R; Lakhtakia R
Med J Armed Forces India; 1998 Jan; 54(1):76-78. PubMed ID: 28775426
[No Abstract] [Full Text] [Related]
28. Line-field confocal optical coherence tomography: A new in vivo assessment tool for cutaneous mycosis fungoides.
Soglia S; Pérez-Anker J; Ghini I; Lenoir C; Maione V; Sala R; Tonon F; Suppa M; Calzavara-Pinton PG; Malvehy J; Venturini M
J Eur Acad Dermatol Venereol; 2024 Mar; 38(3):e296-e298. PubMed ID: 37983937
[No Abstract] [Full Text] [Related]
29. Mycosis fungoides and Sézary syndrome: clinical presentation, diagnosis, staging, and therapeutic management.
Miyashiro D; Sanches JA
Front Oncol; 2023; 13():1141108. PubMed ID: 37124514
[TBL] [Abstract][Full Text] [Related]
30. Cutaneous T-cell lymphoma-Focus on some problems, and some solutions.
Beltraminelli H
Hematol Oncol; 2023 Jun; 41 Suppl 1():20-24. PubMed ID: 37294972
[TBL] [Abstract][Full Text] [Related]
31. Mycosis fungoides and Sézary syndrome.
Lee H
Blood Res; 2023 Apr; 58(S1):66-82. PubMed ID: 37105561
[TBL] [Abstract][Full Text] [Related]
32. Primary cutaneous T-cell lymphoma: a review of the most common entities with focus on recent updates.
Saleh JS; Subtil A; Hristov AC
Hum Pathol; 2023 Aug; 138():76-102. PubMed ID: 37307932
[TBL] [Abstract][Full Text] [Related]
33. Folliculotropic mycosis fungoides associated with follicular mucinosis: A case report and mini review.
Aldayhum MS; Alshahrani MS; Hussein MRA; Alshahrani AS; Hussein TMR
Clin Case Rep; 2024 Apr; 12(4):e8731. PubMed ID: 38585584
[TBL] [Abstract][Full Text] [Related]
34. Decoding Early Mycosis Fungoides: Histopathologic and Immunohistochemical Clues.
Kaya Terzi N
Cureus; 2024 Apr; 16(4):e57545. PubMed ID: 38577165
[TBL] [Abstract][Full Text] [Related]
35. Role of Neutrophil-to-Lymphocyte Ratio (NLR) in Patients with Mycosis Fungoides.
Di Raimondo C; Lombardo P; Tesei C; Esposito F; Meconi F; Secchi R; Lozzi F; Monopoli A; Narducci MG; Scala E; Angeloni C; De Stefano A; Rahimi S; Bianchi L; Cantonetti M
Diagnostics (Basel); 2023 Jun; 13(11):. PubMed ID: 37296831
[TBL] [Abstract][Full Text] [Related]
36. Mycosis fungoides and Sézary syndrome - Review and outlook.
Latzka J; Trautinger F
J Dtsch Dermatol Ges; 2023 Apr; 21(4):386-391. PubMed ID: 36971307
[TBL] [Abstract][Full Text] [Related]
37. Mycosis fungoides and Sézary syndrome.
Jonak C; Tittes J; Brunner PM; Guenova E
J Dtsch Dermatol Ges; 2021 Sep; 19(9):1307-1334. PubMed ID: 34541796
[TBL] [Abstract][Full Text] [Related]
38. Mycosis fungoides and Sézary syndrome: Australian clinical practice statement.
Bhabha FK; McCormack C; Wells J; Campbell BA; Newland K; Lade S; Buelens O; Joske D; Shortt J; Mapp S; Radeski D; Hertzberg M; Khot A; Van Der Weyden C; Khoo C; Hawkes E; Prince HM
Australas J Dermatol; 2021 Feb; 62(1):e8-e18. PubMed ID: 33368169
[TBL] [Abstract][Full Text] [Related]
39. Mycosis fungoides and the Sézary syndrome.
Kim YH; Hoppe RT
Semin Oncol; 1999 Jun; 26(3):276-89. PubMed ID: 10375085
[TBL] [Abstract][Full Text] [Related]
40. [Current therapeutic options in Mycosis fungoides and Sézary syndrome].
Albrecht JD; Nicolay JP
Hautarzt; 2022 Jan; 73(1):75-85. PubMed ID: 34988613
[TBL] [Abstract][Full Text] [Related]
[Previous] [Next] [New Search]
